Core Viewpoint - Ekso Bionics Holdings, Inc. has entered into a private placement agreement to raise approximately $5.9 million through the sale of Series B Preferred Stock and warrants, aimed at enhancing its working capital and corporate purposes [1][3]. Group 1: Private Placement Details - The company will sell 5,852 shares of Series B Preferred Stock with a stated value of $1,000 per share, convertible into 711,922 shares of common stock at a conversion price of $8.22 per share [2]. - The warrants will allow the purchase of up to 355,960 shares of common stock at an exercise price of $8.22 per share, expiring five years from the initial exercise date [2]. - The closing of the private placement is expected around January 22, 2026, pending customary closing conditions [3]. Group 2: Financial Implications - The gross proceeds from the private placement are anticipated to be approximately $5.9 million before deducting fees and expenses [3]. - The net proceeds will be utilized for working capital and general corporate purposes [3]. Group 3: Company Overview - Ekso Bionics is a leading developer of exoskeleton solutions aimed at enhancing human strength, endurance, and mobility in medical and industrial applications [7]. - The company is headquartered in the San Francisco Bay Area and is listed on the Nasdaq Capital Market under the symbol "EKSO" [7].

NEW YORK, Jan. 5, 2026 /PRNewswire/ -- Class Action Attorney Juan Monteverde with Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS Securities Class Action Services Report. The firm is headquartered at the Empire State Building in New York City and is investigating EKSO Bionics Holdings, Inc. (NASDAQ: EKSO) related to its merge with Applied Digital Cloud. Upon completion of the proposed transaction, ...

Core Viewpoint - H.C. Wainwright downgraded Ekso Bionics to Neutral from Buy due to its non-binding merger agreement with Applied Digital Cloud, indicating a shift from its core business strategy [1] Group 1: Company Actions - Ekso Bionics entered into a non-binding merger agreement with Applied Digital Cloud, which is seen as a prudent move given the tough financial environment [1] - The downgrade reflects concerns that Ekso Bionics is moving away from its primary focus on commercializing exoskeletons for health and industrial applications [1]

Core Viewpoint - Ekso Bionics (EKSO) shares surged nearly 100% following Applied Digital's (APLD) announcement of spinning off its cloud segment, which will merge with Ekso to form a new entity called ChronoScale [1]. Group 1: Company Developments - The merger with the spun-off cloud segment is part of a strategic review aimed at unlocking shareholder value for Ekso Bionics [3]. - Ekso Bionics operates in a rapidly expanding market for robotic exoskeletons, which are used for rehabilitation and workplace safety [4]. - Recent healthcare partnerships and industrial deployments have led to a significant revenue growth of 105% sequentially in Q3 [5]. Group 2: Market Position and Valuation - Despite the recent surge, EKSO stock is still down approximately 40% from its year-to-date high [2]. - The price-sales (P/S) multiple for Ekso Bionics is less than 1x, making it an attractive early-stage investment in its market [4]. - The consensus rating for EKSO shares is currently "Moderate Buy," with the highest price target of $9.50 indicating a potential downside of nearly 10% from current levels [7]. Group 3: Technical Analysis - EKSO shares are trading above major moving averages, with a long-term relative strength index (100-day) at nearly 56, suggesting that bullish momentum is still strong [5]. - Investors typically reward companies involved in spinoffs due to anticipated improvements in efficiency and growth prospects [3].

Market Overview - The U.S. stock market is closing 2025 on a cautious note, with major index futures edging lower, extending a three-session losing streak, and hopes for a year-end "Santa Claus" rally fading [1] - Despite the recent pullback, 2025 has been a remarkable year for equities, with the S&P 500 poised for its third consecutive year of double-digit gains [1] Premarket Trading and Futures Movements - As of early Wednesday, U.S. stock futures indicated a softer open, with Nasdaq 100 futures down 0.43%, S&P 500 futures down 0.28%, and Dow Jones futures down 0.14% [2] - The S&P 500, Nasdaq Composite, and Dow Jones all finished slightly lower on Tuesday, marking the third consecutive day of losses [2] Commodities Market - Crude oil futures were trading lower by 0.38%, around $57.72 per barrel, while Gold Spot was down 0.35% to approximately $4,324.59 per ounce [3] Major Market Indexes Performance - The S&P 500 is on track for an annual gain of 17-18%, the Dow Jones has advanced 13-14%, and the Nasdaq Composite has jumped nearly 21% in 2025 [4] - This performance marks the S&P 500's third consecutive year of double-digit returns, a rare achievement since the 1940s [4] Federal Reserve Outlook - The Federal Reserve is expected to cut rates in 2026, with uncertainty regarding the extent and pace due to internal divisions and mixed economic data [6] - The FOMC approved a quarter-point reduction in December 2025, bringing the main interest rate to a range between 3.5% and 3.75% [6] - Inflation remains above the Fed's 2% target, with unemployment rising to 4.6% in November and only 64,000 jobs added [6] Corporate Developments - Vanda Pharmaceuticals shares surged over 18% after receiving FDA approval for its drug NEREUS [13] - Nike shares rose 1.54% following CEO Elliott Hill's purchase of approximately $1 million in company shares [13] - Nvidia's stock surged approximately 180% in 2025, driven by robust demand for AI chips, with ByteDance planning to increase spending on Nvidia's AI chips to around $14 billion in 2026 [13] - Urgent.ly Inc. shares rose significantly after the adjournment of its annual stockholder meeting [13] - Applied Digital announced a proposed merger with EKSO Bionics, leading to a 40% surge in EKSO shares [13] - FONAR Corporation shares surged 28.4% after confirming its acquisition by an insider-led group [13] - Society Pass Incorporated shares jumped 16.4% following a newly priced public offering [13] - Palantir and Tesla saw their shares decline amidst concerns about technology giants' capital expenditures [13] - Boeing shares advanced 0.6% after being awarded an $8.58 billion contract by the Defense Department [13] - Meta Platforms shares ended up 1.1% following its acquisition of an AI startup for over $2 billion [13]

Applied Digital Corp (NASDAQ:APLD) announced plans to spin off its cloud business, combining with Ekso Bionics (EKSO) to create "ChronoScale." Shares of Applied Digital have pulled back from their early-morning surge, last seen trading near breakeven at $24.83, while EKSO is up 94.1% at $10.60 at last look. APLD has been volatile since falling from its Oct. 16, 20-year high of $40.20, but support at the ascending 120-day moving average is keeping pullbacks in check. Since the start of the year, the equity i ...

Core Viewpoint - Halper Sadeh LLC is investigating the fairness of the merger between EKSO Bionics Holdings, Inc. and Applied Digital Cloud for EKSO shareholders [1][2]. Group 1: Investigation Details - The investigation focuses on whether EKSO and its board violated federal securities laws and/or breached fiduciary duties by not obtaining the best possible consideration for shareholders [2]. - The investigation also questions if EKSO disclosed all material information necessary for shareholders to adequately assess and value the merger [2]. Group 2: Potential Actions - On behalf of EKSO shareholders, Halper Sadeh LLC may seek increased consideration, additional disclosures, and other relief related to the proposed transaction [3]. - The legal action would be handled on a contingent fee basis, meaning shareholders would not be responsible for out-of-pocket legal fees or expenses [3]. Group 3: Firm Background - Halper Sadeh LLC represents global investors affected by securities fraud and corporate misconduct, having recovered millions for defrauded investors [4].

Core Viewpoint - Applied Digital and EKSO Bionics announced a proposed business combination to form ChronoScale Corporation, aimed at creating a focused GPU platform for next-generation AI workloads, addressing the growing demand for GPU-accelerated cloud infrastructure [1][2]. Group 1: Proposed Transaction Details - The proposed transaction involves merging Applied Digital's cloud computing business with EKSO, resulting in ChronoScale, which will focus on delivering high-performance compute solutions tailored for AI workloads [1][2]. - Upon completion, Applied Digital is expected to own approximately 97% of the combined entity, with both Applied Digital Cloud and EKSO continuing to operate independently [3]. Group 2: Strategic Rationale - The separation of the accelerated compute platform from Applied Digital's data center operations will allow both businesses to scale independently and pursue distinct growth strategies [2]. - ChronoScale is designed for customers needing predictable performance and rapid deployment, without the limitations of generic cloud environments [2]. Group 3: Financial Performance - Applied Digital Cloud generated approximately $75.2 million in revenue over the twelve months ending August 31, 2025, indicating strong demand for dedicated accelerated compute services [4]. Group 4: Future Outlook - The proposed transaction is expected to close in the first half of 2026, pending customary due diligence and regulatory approvals [6]. - ChronoScale aims to leverage Applied Digital's existing infrastructure to enhance deployment timelines and reduce execution risks as GPU demand increases [5].

Ekso Bionics Holdings, Inc. (EKSO) shares fell 12.75 percent, sliding $0.5802 to $3.97 on Thursday, after the company announced it will become the exclusive U.S. sales agent and distributor for MediTouch's BalanceTutor rehabilitation system. The uses a patented 4D perturbation treadmill to simulate real-world balance challenges, supporting patient safety while improving rehabilitation outcomes.Ekso Bionics is trading at $3.97 versus a previous close of $4.5502 on the Nasdaq. The stock opened at $4.25 and h ...

Core Insights - Ekso Bionics has entered into an agreement with MediTouch to become the exclusive authorized sales agent and distributor of the BalanceTutor rehabilitation system in the United States [1][3] Group 1: Product Overview - The BalanceTutor is a unique rehabilitation system featuring a patented 4D perturbation treadmill that allows patients with balance impairments to respond to unexpected disturbances while walking [2] - The treadmill can move in multiple directions (forward, backward, side-to-side) to simulate realistic balance challenges, ensuring patient safety through an overhead support frame [2] Group 2: Strategic Implications - The partnership with MediTouch is expected to enhance Ekso Bionics' market reach and align with its existing enterprise health exoskeleton solutions, targeting both inpatient and outpatient rehabilitation facilities [3] - The collaboration is seen as a significant milestone for MediTouch, aiming to increase access to innovative rehabilitation technology and assist more individuals in regaining balance and independence [3] Group 3: Company Background - Ekso Bionics specializes in developing exoskeleton solutions that enhance human strength, endurance, and mobility across medical and industrial applications, focusing on improving health and quality of life [4] - MediTouch is committed to creating advanced rehabilitation solutions for various healthcare settings, empowering clinicians and patients with effective rehabilitation tools [5]